Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13450822 | 0.84 | ALDH1A1 (0.45) | GAATP53HSD17B10LMNAPTGDR2 | |
| SCHEMBL8282756 | 0.84 | GAA (0.36) | GAATP53NPC1PKMRAB9A | |
| SCHEMBL4799836 | 0.81 | MAOB (0.49) | TP53LMNAPTGDR2CA2ALDH1A1 | |
| SCHEMBL11242750 | 0.81 | TP53 (0.46) | GAATP53RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL31172078 | 0.79 | NPC1 (0.37) | GAATP53NPC1PKMRAB9A | |
| SCHEMBL28664740 | 0.79 | NPC1 (0.37) | GAATP53NPC1PKMRAB9A | |
| SCHEMBL19251029 | 0.79 | NPC1 (0.37) | GAATP53NPC1PKMRAB9A | |
| SCHEMBL13577241 | 0.79 | MAOB (0.50) | MAOB | |
| SCHEMBL11699485 | 0.78 | ALDH1A1 (0.46) | GAATP53SMN1; SMN2LMNACA2 | |
| SCHEMBL2094298 | 0.78 | DRD4 (0.42) | TP53LMNAPTGDR2PDK2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-08-08 | — | — | US | disclosed |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2454239-B1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2011006903-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | GAA 782/4885TP53 24/4885NPC1 3656/4885 |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | GAA 599/4885TP53 2756/4885NPC1 548/4885 |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | GAA 975/4885TP53 24/4885NPC1 3954/4885 |
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | HSPA2, HSP90AA1, HSP90AB1 | GAA 782/4885TP53 24/4885NPC1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.